Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: Efficacy of 3 dosing strategies

Journal of Clinical Psychiatry

Volumn 67, Issue 10, 2006, Pages 1624-1632

  Kornstein, Susan G ^a,d   Pearlstein, Teri B ^b   Fayyad, Rana ^c   Farfel, Gail M ^c   Gillespie, John A ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c PFIZER INC   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SERTRALINE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LOW DRUG DOSE; LUTEAL PHASE; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MENSTRUAL CYCLE; POST HOC ANALYSIS; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SOCIAL ADAPTATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33751208008     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n1020     Document Type: Article

References (39)

1. Rivera-Tovar AD, Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry 1990;147:1634-1636
2. Wittchen HU, Becker E, Lieb R, et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32:119-132
3. Cohen LS, Soares CN, Otto MW, et al. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women: the Harvard Study of Moods and Cycles. J Affect Disord 2002;70:125-132
4. Sternfeld B, Swindle R, Chawla A, et al. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol 2002;99:1014-1024
5. Spitzer RL, Williams JB, Kroenke K, et al. Validity and utility of the PRIME-MD patient health questionnaire in assessment of 3000 obstetric- gynecologic patients: the PRIME-MD Patient Health Questionnaire Obstetrics-Gynecology Study. Am J Obstet Gynecol 2000;183:759-769
6. Angst J, Sellaro R, Merikangas KR, et al. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001;104: 110-116
7. Ramcharan S, Love EJ, Fick GH, et al. The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors. J Clin Epidemiol 1992;45:377-392
8. Logue CM, Moos RH. Perimenstrual symptoms: prevalence and risk factors. Psychosom Med 1986;48:388-414
9. Johnson SR. The epidemiology and social impact of premenstrual symptoms. Clin Obstet Gynecol 1987;30:367-376
10. Stout AL, Grady TA, Steege JF, et al. Premenstrual symptoms in black and white community samples. Am J Psychiatry 1986;143:1436-1439
11. Dalton K, Dalton ME, Guthrie K. Incidence of the premenstrual syndrome in twins. Br Med J 1987;295:1027-1028
12. van den Akker OB, Stein GS, Neale MC, et al. Genetic and environmental variation in menstrual cycle: histories of two British twin samples. Acta Genet Med Gemellol 1987;36:541-548
13. Kendler KS, Silberg JL, Neale MC, et al. Genetic and environmental factors in the aetiology of menstrual, premenstrual and neurotic symptoms: a population-based twin study. Psychol Med 1992;22:85-100
14. Condon JT. The premenstrual syndrome: a twin study. Br J Psychiatry 1993;162:481-486
15. Kendler KS, Karkowski LM, Corey LA, et al. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 1998;155:1234-1240
16. Roca CA, Schmidt PJ, Rubinow DR. A follow-up study of premenstrual syndrome. J Clin Psychiatry 1999;60:763-766
17. National Institute of Mental Health. NIMH Premenstrual Syndrome Workshop Guidelines. Rockville, Md: National Institute of Mental Health; April 14-15, 1983
18. World Health Organization. International Classification of Diseases 10th Revision. Geneva, Switzerland: World Health Organization; 1996
19. American College of Obstetricians and Gynecologists. Premenstrual syndrome: clinical management guidelines for obstetrician-gynecologists. ACOG Practice Bulletin 2000;15:1-9
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington, DC: American Psychiatric Association; 1994
21. Freeman EW, Rickels K, Sondheimer SJ, et al. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 1999;56:932-939
22. Pearlstein T, Steiner M. Non-antidepressant treatment of premenstrual syndrome. J Clin Psychiatry 2000;61(suppl 12):22-27
23. Wyatt K, Dimmock P, Jones P, et al. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 2001;323:776-780
24. Wyatt KM, Dimmock PW, Jones PW, et al. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: a systematic review. BMJ 1999;318:1375-1381
25. Pearlstein T. Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard? Drugs 2002;62: 1869-1885
26. Wyatt KM, Dimmock PW, O'Brien PMS. Selective serotonin reuptake inhibitors for premenstrual syndrome. The Cochrane Library, issue 4, 2005. Available at: http://www.mrw.interscience.wiley.com/cochrane/ clsysrev/articles/CD001396/frame.html. Accessed Jan 11, 2006
27. Freeman EW, DeRubeis RJ, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Res 1996;65:97-106
28. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication (ADM) 76-338; Rockville, Md: National Institute of Mental Health; 1976: 218-222
29. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-326
30. Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry 1976;33:1111-1115
31. Freeman EW, Rickels K. Characteristics of placebo responses in medical treatment of premenstrual syndrome. Am J Psychiatry 1999; 156:1403-1408
32. Khan A, Kolts RL, Thase ME, et al. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 2004;161:2045-2049
33. Piercy MA, Sramek JJ, Kurtz NM, et al. Placebo response in anxiety disorders. Ann Pharmacother 1996;30:1013-1019
34. Pearlstein TB, Halbreich U, Batzar ED, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000; 61:101-109
35. Halbreich U, Bergeron R, Yonkers KA, et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002;100:1219-1229
36. Cohen LS, Soares CN, Lyster A, et al. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 2004; 24:540-543
37. Cohen LS, Miner C, Brown EW, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002;100:435-444
38. Freeman EW, Sondheimer SJ, Sammel MD, et al. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry 2005;66:769-773
39. Steiner M, Hirschberg AL, Bergeron R, et al. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 2005;193:352-360